University of Utah
utah.eduTotal trials
967
Active
219
Phase 3
40
Total enrollment
781,228
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 74 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Levonorgestrel 52 MG Intrauterine System | — | — | — | — | — | 1 | |
| Levonorgestrel 1.5 mg and Piroxicam 40 mg | — | — | — | — | — | 1 | |
| Oral LNG + Placebo | — | — | — | — | — | 1 | |
| Propofol | — | — | — | — | — | 1 | |
| Nivolumab | — | — | — | — | 8 | ||
| Metformin | — | — | — | 5 | |||
| Durvalumab | — | — | — | — | 3 | ||
| Ipilimumab | — | — | — | — | 4 | ||
| Rituximab | — | — | — | — | 3 | ||
| Pirtobrutinib | — | — | — | — | — | 2 | |
| Loncastuximab tesirine | — | — | — | — | — | 2 | |
| Bortezomib | — | — | — | — | — | 2 | |
| Riluzole 50 MG | — | — | — | — | — | 1 | |
| Sildenafil Oral Suspension | — | — | — | — | — | 1 | |
| Enfortumab vedotin | — | — | — | — | — | 1 | |
| Rituximab or rituximab biosimilar | — | — | — | — | — | 1 | |
| XL092 | — | — | — | — | — | 1 | |
| Transdermal estrogen | — | — | — | — | — | 1 | |
| Nicotinamide | — | — | — | — | — | 1 | |
| Atezolizumab | — | — | — | — | — | 1 | |
| Cabozantinib S-malate | — | — | — | — | — | 1 | |
| Inebilizumab | — | — | — | — | — | 1 | |
| Cobimetinib | — | — | — | — | — | 1 | |
| Mosunetuzumab | — | — | — | — | — | 1 | |
| Pneumococcal 20-valent Conjugate Vaccine | — | — | — | — | — | 1 | |
| Pneumococcal Polyvalent Vaccine | — | — | — | — | — | 1 | |
| Axatilimab | — | — | — | — | — | 1 | |
| Pemetrexed | — | — | — | — | — | 1 | |
| Carboplatin | — | — | — | — | — | 1 | |
| MORE+KAP | — | — | — | — | — | 1 | |
| Defactinib | — | — | — | — | — | 1 | |
| Avutometinib | — | — | — | — | — | 1 | |
| Encorafenib | — | — | — | — | — | 1 | |
| relugolix + ARPI | — | — | — | — | — | 1 | |
| Intermittent- Relugolix or androgen deprivation therapy (ADT) + ARPI | — | — | — | — | — | 1 | |
| relugolix or androgen deprivation therapy (ADT) + ARPI | — | — | — | — | — | 1 | |
| relugolix + ARPI. | — | — | — | — | — | 1 | |
| Topical Tretinoin | — | — | — | — | — | 1 | |
| Isatuximab | — | — | — | — | — | 1 | |
| Pemigatinib | — | — | — | — | — | 1 |
34 more active programs hidden
Next readouts
- 2022-12-31
- 2023-12-30
- 2024-01-29
- 2024-10-30
- 2024-12-06
- 2025-02-04
- 2025-02-10
- 2025-02-18
- 2025-04-02
- 2025-04-22
Top conditions
- Cancer31
- Pain23
- Chronic Pain20
- Breast Cancer20
- Low Back Pain17
- Contraception15
- Obesity15
- Stroke14
Frequently asked questions about University of Utah
- How many clinical trials does University of Utah have on ClinicalTrials.gov?
- University of Utah is listed as the lead sponsor on 967 clinical trials in ClinicalTrials.gov, 219 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Utah's trials are in Phase 3?
- 40 of University of Utah's trials are in Phase 3, spread across 74 active drug programs.
- What therapeutic areas does University of Utah focus on?
- University of Utah's most-studied conditions on ClinicalTrials.gov are Cancer, Pain, Chronic Pain, Breast Cancer, Low Back Pain.
- When are University of Utah's next clinical trial readouts?
- University of Utah has 10 upcoming primary-completion readouts tracked here; the soonest is “Neural and Antidepressant Effects of Propofol”, expected around 2022-12-31.